Voltage-gated sodium channels (Navs) are an important family of transmembrane ion channel proteins and Nav drug discovery is an exciting field. Pharmaceutical investment in Navs for pain therapeutics has expanded exponentially due to genetic data such as SCN10A mutations and an improved ability to establish an effective screen sequence for example IonWorks Barracuda®, Synchropatch® and Qube®. Moreover, emerging clinical data (AZD-3161, XEN402, CNV1014802, PF-05089771, PF-04531083) combined with recent breakthroughs in Nav structural biology pave the way for a future of fruitful prospective Nav drug discovery. © 2014 Elsevier Ltd. All rights reserved.
CITATION STYLE
Bagal, S. K., Chapman, M. L., Marron, B. E., Prime, R., Storer, R. I., & Swain, N. A. (2014, August 15). Recent progress in sodium channel modulators for pain. Bioorganic and Medicinal Chemistry Letters. https://doi.org/10.1016/j.bmcl.2014.06.038
Mendeley helps you to discover research relevant for your work.